EUCTR2008-002780-13-ES进行中（未招募）1 期
Estudio multicéntrico, doble enmascarado, de tres meses para comparar la seguridad y eficacia de la combinación fija de Travoprost/Brinzolamida colirio en suspensión vs TRAVATAN vs AZOPT en pacientes con glaucoma de ángulo abierto o hipertensión ocular.A Three-Month, Multicenter, Double-Masked Study Comparing the Safety and Efficacyof the Fixed Combination Travoprost + Brinzolamide Eye Drops, Suspension vsTravatan vs Azopt in Patients with Open-Angle Glaucoma or ocular Hypertension - Travoprost / Brinzolamide Fixed Combination vs. TRAVATAN and vs. AZOPT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients, of either sex and any race, 18 years of age or older, diagnosed with open angle glaucoma (with or without pseudoexfoliation or pigment dispersion
- •component) or ocular hypertension.
- •2. Patients inadequately controlled on a current stable (i.e., at least 4 weeks)
- •IOP-lowering medication. Inadequately controlled is defined as having a mean IOP
- •= 18 mmHg in at least one eye during the Screening Visit. The same eye(s) must qualify at both time points.
- •3. Patients must meet the following IOP entry criteria in at least one eye:
- •For each qualifying eye, the mean IOP must be:
- •= 24 mmHg and = 36 mmHg at the 9:00 time point at both Eligibility Visits 1 and
- •= 21 mmHg and = 36 mmHg at the 11:00 and 16:00 time points at both Eligibility
- •Visits 1 and 2.
- •The mean IOP in either eye at the Eligibility Visits 1 and 2 must not be greater
- •than 36 mmHg at any time point.
- •The same eye(s) must qualify at all qualifying time points at both Eligibility Visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Females of childbearing potential (those who are not surgically sterilized or at least two years post-menopausal) are excluded from participation in the study if they meet any one of the following conditions:
- •- They are currently pregnant or,
- •- They have a positive result on the urine pregnancy test at the Screening Visit or,
- •- They intend to become pregnant during the study period or,
- •- They are breast-feeding or,
- •- They are not using highly effective birth control measures
- •2. Patients with any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component) or ocular hypertension.
- •3. Patients with iridocorneal angle Shaffer grade < 2 (extreme narrow angle with complete or partial closure) angle in either eye, as measured by gonioscopy (see Section 18.1.4.).
- •4. Patients with a cup/disc ratio greater than 0.80 (horizontal or vertical measurement) in either eye.
- •5. Patients with severe central visual field loss in either eye. Severe central field loss is defined as a sensitivity of = 10 dB in at least 2 of the 4 visual field test points closest to the point of fixation (see Section 9.4.5. for details on the procedure).
- •6. Current chronic, recurrent or severe inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis), or current other severe ocular pathology (including severe dry eye) that would affect the conduct of the study.
- •7. History of ocular trauma within the past 6 months.
- •8. Intraocular surgery within the past 6 months.
- •9. Ocular laser surgery within the past 3 months.
- •10. Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal) (see Section 9.4.8. for details on the procedure).
- •11. Current ocular infection or inflammation, or history of ocular infection or inflammation within the past 3 months, as determined by patients’ history and/or examination.
- •12. History of or current clinically relevant or progressive retinal disease, such as retinal degeneration, diabetic retinopathy or retinal detachment.
- •13. Any abnormality preventing reliable applanation tonometry.
- •14. History of, or current evidence of severe illness or any other conditions which would make the patient, in the opinion of the Investigator, unsuitable for the study.
- •15. History of severe or serious hypersensitivity to prostaglandin drugs or their analogues, CAIs or to any components of the study medications. For listings of additional formulation components present in the study medications, see the Clinical Investigator’s Brochure for Travoprost / Brinzolamide which includes the Summary of Product Characteristics for TRAVATAN and AZOPT.
- •16. Less than 30 days on stable dosing regimen before the Screening Visit with any medications or substances administered by any route and used on a chronic basis that may affect IOP, including, but not limited to, beta-adrenergic blocking agents.
- •Note: Patients must be on a stable dosing regimen of medications affecting IOP for at least 30 days prior to the Screening Visit and must not change the dosing regimen during the eligibility period. Any change in dosage or addition of such medication(s) during the study must be documented in the patient’s chart.
- •17. Use of any additional topical or systemic ocular hypotensive medication during the study.
研究者
相似试验
进行中（未招募）
1 期
Estudio multicéntrico, doble enmascarado, de doce meses con la combinación fija de Travoprost/Brinzolamida QD AM y la combinación fija de Travoprost/Brinzolamida QD PM versus COSOPT BID en pacientes con glaucoma de ángulo abierto o hipertensión ocular.A twelve-month, multicenter, double-masked study of Travoprost / Brinzolamide fixed combination QD AM and Travoprost / Brinzolamide fixed combination QD PM versus COSOPT BID in patients with open-angle glaucoma or ocular hypertension - Travoprost / Brinzolamide Fixed Combination Once-Daily vs. COSOPTGlaucoma de ángulo abierto o hipertensión ocularOpen-angle glaucoma or Ocular hypertensionMedDRA version: 9.1Level: LLTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: PTClassification code 10030348Term: Open angle glaucomaMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersMedDRA version: 9.1Level: LLTClassification code 10030043Term: Ocular hypertensionMedDRA version: 9.1Level: PTClassification code 10030043Term: Ocular hypertensionEUCTR2008-002781-66-ESAlcon Research, Ltd.
进行中（未招募）
不适用
Estudio multicéntrico, con doble enmascaramiento, aleatorizado y paralelo de la seguridad y eficacia de la solución oftálmica sin conservantes de bimatoprost al 0,03% y timolol al 0,5% en comparación con GANFORT® (solución oftálmica de bimatoprost al 0,03% y timolol al 0,5%) una vez al día durante 12 semanas en pacientes con glaucoma o hipertensión ocular. //A Multicenter, Double-masked, Randomized, Parallel Study of the Safety and Efficacy of Bimatoprost 0.03%/Timolol 0.5% Preservative-free Ophthalmic Solution Compared with GANFORT® (bimatoprost 0.03%/timolol 0.5% ophthalmic solution) Once Dailyfor 12 Weeks in Patients with Glaucoma or Ocular HypertensioGlaucoma o Hipertensión Ocular //Glaucoma or Ocular HypertensionMedDRA version: 12.1Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionMedDRA version: 12.1Level: LLTClassification code 10008833Term: Chronic angle-closure glaucomaMedDRA version: 12.1Level: LLTClassification code 10009034Term: Chronic open angle glaucomaEUCTR2010-021507-24-ESAllergan Limited500
进行中（未招募）
1 期
Estudio doble-ciego, doble enmascaramiento, con asignación aleatoria a los grupos de tratamiento y con grupos paralelos, que evalúa la seguridad de la combinación salmeterol/propionato de fluticasona (Seretide), administrando dos inhalaciones de 25/50 mcg dos veces al día, con propionato de fluticasona (Flixotide), administrando dos inhalaciones de 50 mcg dos veces al día, ambos administrados mediante ......AsmaMedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-001417-16-ESGlaxoSmithKline S.A.351
进行中（未招募）
1 期
Estudio multicéntrico, aleatorizado, doble enmascarado de seis semanas para evaluar la eficacia y seguridad de la administración única por la mañana de Travoprost/Timolol comparada con la administración dos veces al día de Dorzolamida/Timolol en pacientes con glaucoma de ángulo abierto o hipertensión ocular. - Travoprost 0.004%/Timolol 0.5% and Dorzolamide 2%/Timolol 0.5%EUCTR2005-004767-34-ESAlcon Research, Ltd.450
进行中（未招募）
不适用
A multicenter, Investigator - masked, parallel-group, randomized study of the efficacy and safety of loteprednol etabonate 0.5% eyedrops versus dexamethasone 0.1% eyedrops in the treatment of ocular inflammation following cataract surgery. - Study#541-Lteprednol etabonate vs DexamethasoneSubjects scheduled to undergo cataract surgeryMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2007-005621-30-ITBAUSCH&LOMB190